Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study.
Ahn IE, Farooqui MZH, Tian X, Valdez J, Sun C, Soto S, Lotter J, Housel S, Stetler-Stevenson M, Yuan CM, Maric I, Calvo KR, Nierman P, Hughes TE, Saba NS, Marti GE, Pittaluga S, Herman SEM, Niemann CU, Pedersen LB, Geisler CH, Childs R, Aue G, Wiestner A.
Ahn IE, et al. Among authors: lotter j.
Blood. 2018 May 24;131(21):2357-2366. doi: 10.1182/blood-2017-12-820910. Epub 2018 Feb 26.
Blood. 2018.
PMID: 29483101
Free PMC article.
Clinical Trial.